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Abstract
Background: Palliative radiotherapy (PRT) can significantly improve quality of life for patients dying of cancer with
bone metastases. However, an aggressive cancer treatment near end of life is an indicator of poor-quality care. But
the optimal rate of overall palliative RT use near the end of life is still unknown. We sought to determine the
patterns of palliative radiation therapy (RT) utilization in patients with bone metastases towards their end of life in a
population-based, publicly funded health care system.
Methods: All consecutive patients with bone metastases treated with RT between 2007 and 2011 were identified
in a provincial Canadian cancer registry database. Patients were categorized as receiving RT in the last 2 weeks, 2–4
weeks, or >4 weeks before their death. Associations between RT fractionation utilization by these categories, and
patient and provider characteristics were assessed through logistic regression.
Results: Of the 16,898 courses 1734 (10.3) and 709 (4.2 %) were prescribed to patients in the last 2–4 weeks and
<2 weeks of their life, respectively. Primary lung (8 %) and gastrointestinal (6.9 %) cancers received palliative RT
more commonly in the last 2 weeks of life (OR 3.72 [2.86–4.84] & 3.33 [2.42–4.58] respectively, p <0.001). Among the
709 patients who received RT in the last 2 weeks of life, 350 (49), 167 (24), and 127 (18 %) were for spine, pelvis,
and extremity metastases, respectively. RT was prescribed most frequently to spine (5 %) and extremity (4 %)
metastases p <0.001 in the last two weeks of life, though only varied between 1 % (sternum) and 5 % (spine) by
site of metastases. Single fraction RT was prescribed more commonly in the last 2 weeks of life (64.2 %), compared
to individuals who received RT 2–4 weeks (54.5), and >4 weeks (47.9 %) before death (p <0.001).
Conclusions: This population-based analysis found that only 4 % of patients with bone metastases received
radiation therapy during the last 2 weeks of their life in our population-based, publicly funded program, though it
was significantly higher in patients with lung cancer and those with metastases to the spine or extremity.
Appropriately, use of multiple fractions palliative RT was less common in patients closer to death.
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Background
Approximately half of prescribed radiotherapy (RT) is
delivered with palliative intent across North America
[1, 2]. Palliative RT has numerous indications, and
primarily includes the treatment of painful bone
metastases [2]. Palliative RT for bone metastases pro-
vides successful pain relief, preservation of function,
and maintenance of skeletal integrity with minimal risk
of serious side effects [3, 4].
Palliative RT for bone metastases reduces pain in the
majority of patients, though often takes several weeks [5].
The use of palliative RT use in the final weeks of life of
therefore may have limited clinical use and may actually
impair quality of life for patients and their families near
the end of life [5].
The optimal rate of palliative RT use near the end of
life is still unknown [5]. The use of systemic therapies at
the end of life has been extensively studied, and same is
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warranted for optimal rate of palliative RT usage in such
patients [6, 7]. An overly aggressive cancer treatment at
the end of life may be an indicator of poor-quality care
[6–8]. The total palliative RT dose, the dose per fraction
and the technique of irradiation use may vary with the
treatment aim in patients with bone metastases [9].
British Columbia (BC) provides 100 % of the radiation
therapy in the province as a, publicly-funded service
with no direct costs to patients. We previously published
initial results demonstrating variation in RT prescribing
practices for bone metastases in BC, where we demon-
strated an association between fractionation and prognosis
[10]. The primary objective of this current study is to
explore the patterns of RT usage in patients with bone
metastases towards their end of life. Understanding the
patterns of palliative RT in patients with bone metastases
will help us measure our quality and consistency of end of
life care across the province.
Methods
Study design and cohort selection
This population-based retrospective study used
administrative data to define a cohort of patients
who received palliative RT for bone metastases during
2007 through 2011. This study was approved by the joint
University of British Columbia and BC Cancer Agency
(BCCA) Research Ethics Board.
Data source and extraction
Patient data was extracted through the BCCA Cancer
Agency Information System. The RT parameters were
retrieved from BCCA’s RT database [11] and included
site of RT, date of RT, dose, and fractionation. These
databases were used to abstract patient, provider and
treatment characteristics. Patient chart reviews, and re-
view of RT plans where necessary, were performed to iden-
tify the various patient and physician related parameters
associated with palliative RT in bone metastases. The
provincial radiation therapy facilities up to 2011 were
located in Abbotsford, Kelowna, Surrey, Vancouver &
Victoria.
Patient and treatment variables
The patients who received RT for bone metastases at the
BC Cancer Agency from 2007 to 2011 were included in
the analysis. The commonly occurring primary tumour
sites were categorized as prostate, breast, lung, lymphoma,
and gastro-intestinal (GI). The key sites of skeletal metas-
tases were classified as spine, pelvis, extremity, rib,
sternum, and ‘skull’, the latter of which included orbit and
jaw. For descriptive analyses, RT fractionation was classi-
fied into single fraction (SF) or multiple fractions (MF).
Statistical analysis
Time to death was calculated from last course of palliative
RT. This time interval (in weeks) was categorized into
three groups :< 2, and 2–4, and > 4 weeks. Association be-
tween these categories and the variables was analyzed
through descriptive statistics, and chi-square test.
Subsequently, univariable and multivariable linear
regression analyses were performed to assess these
associations. P values were two-sided, and values less
than .05 were considered statistically significant. Analyses
were conducted using the SPSS statistical software pack-
age, version 19.0 (Chicago, IL).
Results
A total of 16,898 courses of palliative RT were delivered
to 8301 patients from 2007 to 2011. Baseline patient and
treatment related factors are summarized Table 1, and
have also been presented in an earlier publication10. The
median survival for the entire cohort was 18 weeks
(95 % CI 17.49–18.51).
Of the 16,898 courses 1734 (10.3) and 709 (4.2 %)
were prescribed to patients in the last 2–4 weeks and
<2 weeks of their life, respectively (Table 1). Table 2
highlights the univariate analysis on the utilization of
palliative RT in the last 2 weeks of life. Single fraction
RT was prescribed more frequently in patients with a
shorter time from RT to end of life (Fig. 1).
Multivariable logistic regression is presented in Table 3,
demonstrating a significant association between use of
RT in the last 2 weeks of life and site of primary, site of
metastases, and BCCA Centre (Table 3). Lung cancer
patients (p < 0.001), and those receiving RT to spinal
metastases (p < 0.001), were more likely to receive RT in
the last 2 weeks of life (Table 3).
Discussion
We demonstrated that 4 and 10 % of palliative RT
courses were delivered to patients with bone metastases
during the last 2 weeks, or last 2–4 weeks of their life,
respectively in a large population based, publicly
funded provincial RT program. Patients with lung and
gastrointestinal cancers, or those receiving RT to their
spine or extremity, were most likely to receive RT near
the end of their life. Appropriately, longer multiple
fraction (MF) RT courses were utilized less frequently
for patients near their end of life.
Our finding of a 4 and 10 % utilization of palliative RT
for bone metastases in last 2 or 2–4 weeks of life, though
on the low end, are consistent with previous literature.
The reported overall palliative RT utilization rates dur-
ing the last 2 weeks of life are in the range of 2.2–14 %
[2, 12–16]. Our relatively lower utilization rates of
palliative RT for bone metastases in this study could be
multifactorial, including accurate prognostication by
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treating physicians, a lack of financial incentive to offer
RT in this publicly funded system, or patient’s choice to
decline treatment [10, 17] Unfortunately, this cannot be
assess in a retrospective study design.
Other authors state that the choice to offer palliative
RT should be guided by life expectancy, though may also
be influenced by a patient’s site of primary disease or
Table 2 Clinical and provider characteristics associated with the
use of palliative RT utilization in the last 2 weeks of life
Characteristic Proportion who
received RT in the
last 2 weeks of life
P value
Age (years) <51 (n =1364) 5.0 % 0.27
51–70 (n =7477) 4.2 %
>70 (n =8057) 4.0 %
Male (n =8491) 4.0 % 0.14
Primary tumour Prostate (n =3218) 2.2 % <0.001
Breast (n =3959) 1.3 %
Lung (n =3777) 7.9 %
Hematological (n =1887) 3.0 %
Gastrointestinal (n =1319) 6.9 %
Other (n =2738) 5.1 %
Skeletal
metastasis
Spine (n =7134) 4.9 % <0.001
Pelvis (n =4826) 3.5 %
Extremity (n =2897) 4.4 %
Ribs (n =1362) 3.5 %
Skull (n =393) 3.8 %
Sternum (n =286) 1.0 %
BCCA centre Abbotsford (n =946) 4.4 % 0.01
Kelowna (n =3221) 3.3 %
Surrey (n =2750) 4.8 %
Vancouver (n =6056) 3.9 %
Victoria (n =3925) 4.8 %



























Time (from last palliative RT to death)
Fig. 1 Percentage utilization of single fraction radiation therapy (SFRT), by time from last course of RT to death
Table 1 Baseline patient, treatment, and provider characteristics
Proportion Proportion





Age (years) <51 8.1 % 8.3 %
51–70 44.2 % 45.8 %
>70 47.7 % 45.8 %
Male 50.2 % 47.5 %
Primary tumour Prostate 19.0 % 10.2 %
Breast 23.4 % 7.3 %
Lung 22.4 % 42.0 %
Hematological 11.2 % 8.0 %
GI 7.8 % 12.8 %
others 16.2 % 19.6 %
Skeletal metastasis Spine 42.2 % 49.4 %
Pelvis 28.6 % 23.6 %
Extremity 17.1 % 17.9 %
Ribs 8.1 % 6.6 %
Sternum 1.7 % 0.4 %
Skull 2.3 % 2.1 %
SFRT 49.2 % 64.2 %
BCCA centre Abbotsford 5.6 % 5.9 %
Kelowna 19.1 % 15.1 %
Surrey 16.3 % 18.6 %
Vancouver 35.8 % 33.7 %
Victoria 23.2 % 26.7 %
SFRT single fraction radiation therapy, BCCA british columbia cancer agency
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area requiring palliation [18–20]. Indeed, we found a
significant variation in the use of RT near the end of life,
based on primary tumor site (most common for lung
and GI cancer) and site requiring palliative RT (most
common for spine and extremity) (Tables 2 and 3). We
hypothesize the higher use of end of life RT in lung and GI
cancers may be a factor of their worse prognosis, where
treating physicians may be less accurately predicting their
poor prognosis. Perhaps the use of prognostic indices could
decrease the use of potential futile RT near the end of life,
which unfortunately we cannot assess within this
retrospective study [5, 21–23].
Furthermore, we hypothesize that the more frequent
use of RT near the end of life for spine and extremity
metastases is related to the severity of the symptoms
they produce. As an example, physicians are likely more
reluctant to withhold RT for a spinal cord compression
or a fractured extremity, than they are for a fractured rib
or painful sternum, irrespective of prognosis. We
propose that physicians adopt more uniform use of
prognostic tools before offering palliative RT, as it is un-
likely that patients receiving RT in the last 2 weeks, even
if they are suffering from a spinal cord compression or
fractured extremity, given the required 2–4 weeks to see
a clinical benefit. Finally, a more convenient and appro-
priate single fraction RT (SFRT) was prescribed in 64 %
of the palliative RT courses to patients who died within
2 weeks of receiving RT. Multiple studies have shown
and confirmed the benefit and efficacy of SFRT near end
of life [18, 24, 25].
This study should be interpreted in the context of its
strengths and limitations. Unfortunately, due to the
retrospective nature of the study, information on pa-
tients’ cultural beliefs, their decision about treatment,
hospital admission, or whether the bone metastases
were complicated by fracture or neurological comprom-
ise was not available. Further, the efficacy of palliative
RT in terms of pain control was also not analyzed
due to the nature of study design. However, this
population-based provincial study is relatively free
from referral and selection bias, and choice of RT pre-
scription is not influenced by physician remuneration or
patient’s ability to pay in this public healthcare model with
physicians on salary.
Conclusions
This population-based analysis found that only 4 and 10 %
of patients with bone metastases received radiotherapy
during the last 2 weeks, or 2–4 weeks of their life, respect-
ively. Radiotherapy near the end of life was used most
frequently for lung and gastrointestinal cancers, poten-
tially as a result of their inherently worse prognosis which
physicians are not accurately predicting. End of life RT
was also used frequently for patients receiving RT to the
spine or extremity, which we hypothesize, is because of
the potential severity of symptoms in these sites, such as
spinal cord compression or fractured extremity. However,
given the likely futility in offering RT during the last
two weeks of life, our research supports the more
widespread adoption of prognostic tool use prior to
prescribing palliative RT. Appropriately, the use of
multiple fractions palliative RT course was less fre-
quently used in patients with a shorter lifespan.
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Table 3 Multivariable logistic regression analysis on palliative RT
utilization in the last 2 weeks of life
Characteristic Odds ratio to
receive RT in last















Breast 0.57 0.40–0.82 0.002
Lung 3.72 2.86–4.84 <0.001
Haematological 1.29 0.91–1.85 0.15
Gastrointestinal 3.33 2.42–4.58 <0.001




Pelvis 0.67 0.55–0.81 <0.001
Extremity 0.87 0.71–1.08 0.21
Ribs 0.66 0.48–0.90 0.01
Sternum 0.22 0.07–0.69 0.01




Abbotsford 1.14 0.81–1.59 0.46
Kelowna 0.86 0.68–1.09 0.20
Surrey 1.29 1.09–1.62 0.03
Victoria 1.34 1.09–1.62 0.005
RT radiation therapy, BCCA british columbia cancer agency
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